Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab + first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.

Authors

Timothy Jay Price

Queen Elizabeth Hospital, University of Adelaide, Woodville, Australia

Timothy Jay Price , Lin Shen , Brigette Ma , Regina Esser , Wen-Feng Chen , Peter Gibbs , Robert S.C. Lim , Ann-Lii Cheng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 Gastrointestinal Cancers Symposium

bookmark_border

Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab + first-line (1L) FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.

First Author: Timothy Jay Price

insert_chart_outlined

Poster

2015 Gastrointestinal Cancers Symposium

bookmark_border

Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).

First Author: Ann-Lii Cheng

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Prognostic role of TP53 variants in the phase III study of FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (ERMES study).

First Author: Nicola Normanno

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Emergence of RAS mutations in RAS wild type metastatic colorectal cancer patients receiving cetuximab as first-line treatment: A prospective study.

First Author: Hsiang-Lin Tsai